VALAPODYN - Validated Predictive Dynamic Models of Complex Intracellular Pathways Related to Cell Death and Survival (FP6-LIFESCIHEALTH) (2006-10-01 - 2009-09-30) (»add to infobox)

Antoine DEPAULIS, Alexander KEL, Todor VUJASINOVIC, Despina SANOUDOU, Edwin DE PAUW, Hermona SOREQ, Raffaella CATENA

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR714 - Isère) (France), BIOBASE GMBH (DE91B - Wolfenbüttel) (Germany), HELIOS BIOSCIENCES SARL (FR107 - Val-de-Marne) (France), FOUNDATION OF BIOMEDICAL RESEARCH OF THE ACADEMY OF ATHENS (GR300 - Attiki) (Greece), UNIVERSITE DE LIEGE (BE332 - Arr. Liège) (Belgium), THE HEBREW UNIVERSITY OF JERUSALEM (ME04 - Israel) (Israel), ALMA CONSULTING GROUP SAS (FR716 - Rhône) (France)

VALAPODYN seeks to advance the development of multidisciplinary functional genomics relating to complex biological processes & cellular networks. The project concerns both DNA & protein applications, followed by innovative dynamic modelling of pathological disease states such as epilepsy, cancer in order to validate the model. The overall aim is to develop an innovative System Biology approach in order to model the dynamics of Molecular Interaction Networks (MIN) related to cell death & survival in the organism. The future dynamic model will be dedicated to selection of drug targets designed to treat human pathologies such as epilepsy, cancer, neurodegenerative diseases. The overall result of dynamic modelling will be an immediate selection of the most efficient putative therapeutic targets, decreasing by at least 10 times the number to study & thus increasing cost effectiveness. S&T objectives are: Pathways analysis: functional annotation of genes & proteins, investigation of structure & dynamics of signal transduction & transcription regulatory networks.; Predictive bioinformatics platform for dynamic modelling: to use innovative biomathematics/bioinformatics to integrate experimental MIN data with biological tissue & pathological states data obtained through the use of transcriptomic & proteomic approaches.; Bioinformatics: to set up a highly specialised database on genomics & proteomics of MIN modelling.; Pathological tissue & animal models: to use novel animal models to evaluate local expression genes/proteins in neurodegenerescence.; Microarrays: to set up a network of microarrays using the Codelink platform.; Proteomics: to form a network of advanced quantitative methods in proteomics technologies (MALDI, ICAT, 2-DPAGE, Heavy Peptides isotopic dilution).; Neuroprotective molecules: to characterise molecules (or combination of molecules) in the MIN of neurodegeneration (NDG) which will have an effect in stopping or curing NDG

PERSONS (7/7)

RELATED NAVIGATION AREA(S) (3/3)